A twelve-month projection to September 2022 of the Covid-19 epidemic in the UK using a Dynamic Causal Model

Authors

Cam Bowie

Retired Director of Public Health, Somerset, UK

Retired Professor of Community Health, College of Medicine, University of Malawi, Blantyre, Malawi

Karl Friston

The Wellcome Centre for Human Neuroimaging, University College London, London, WC1N 3BG, UK

Abstract

Objectives

Predicting the future UK Covid-19 epidemic allows other countries to compare their epidemic with one unfolding without public health measures except a vaccine programme.

Methods

A Dynamic Causal Model (DCM) is used to estimate the model parameters of the epidemic such as vaccine effectiveness and increased transmissibility of alpha and delta variants, the vaccine programme roll-out and changes in contact rates. The model predicts the future trends in infections, long-Covid, hospital admissions and deaths.

Results

Two dose vaccination given to 66% of the UK population prevents transmission following infection by 44%, serious illness by 86% and death by 93%. Despite this, with no other public health measures used, cases will increase from 37 million to 61 million, hospital admission from 536,000 to 684,000 and deaths from 136,000 to 142,000 over twelve months.

Discussion

Vaccination alone will not control the epidemic. Relaxation of mitigating public health measures carries several risks – overwhelming the health services, the creation of vaccine resistant variants and the economic cost of huge numbers of acute and chronic cases.

Introduction

The recent abandonment of meaningful public health control measures in the UK in August 2021 provides a natural experiment offering a base-line control population for other countries to assess the effects of their own public health interventions. It does so by providing a fertile opportunity for Covid-19 to spread throughout the population for months to come. How many people will be infected in the next year? How many will suffer long-Covid? How many more people will die of Covid-19? How effective are the vaccines used in the UK - BNT162b2 (38%) and ChAdOx1 (61%)? What will be the likely re-infection rate as vaccine induced immunity wains?

Dynamic Causal modelling (DCM) is well-suited for predicting the effects of letting the virus sweep through the population because it combines conventional epidemiological models with behavioural modelling at the population level (i.e., it models and predicts both fluctuations in prevalence and contact rates) [1]. Its

predictions can provide a base-line for other countries as they monitor the effects of their public health control efforts. “If you do nothing except vaccinate – this is what will happen”.

Methods

Dynamic causal models

An advantage of dynamic causal models (DCMs) is that the models are designed to continually assimilate data and modify model parameters, such as transmissibility of the virus, changes in social distancing and vaccine coverage—to accommodate changes in population dynamics and virus behaviour. The latest model (25th September 2021) was used to explore the effect of increased ease of transmission of the Delta variant and the likely seasonal effect of the coming winter. Vaccine effectiveness with Delta and the curtailment of social distancing as well as the potential benefit of a successful FTTIS scheme were also incorporated into the model.

The model is fully described and a weekly dashboard provides up-to-date estimates and projections [2]. The software is freely available and can be used using datasets from other countries [3–7]. The following section describes the features of the model for non-modelling experts.

The model includes all the standard SEIR (susceptible, exposed, infected, removed) features of the commonly used models of infectious disease but in addition incorporates the interactions between the different variables. For example, people are more likely to stay at home if the prevalence is high or if they have not been immunised. These dependencies are estimated and only retained if they improve the ability of the model to account for the data. Having optimised the model and model parameters, one can then proceed with scenario modelling to evaluate the effect of interventions such as the influence of an enhanced FTTIS system on the epidemic.

Standard SEIR models depend on the choice of parameters, some of which are unknown empirically and must be guessed. Dynamic causal modelling is, by comparison, relatively assumption free. However, one must specify prior ranges for parameters (just like for SEIR models) but the DCM adjusts the parameters to fit the data in the most efficient and parsimonious way possible. Not only does the model provide estimates and projections of variables such as the death rate, the effective reproductive number, incidence, and prevalence but it also estimates of transmissibility, susceptibility, latent resistance, herd immunity, expected social distancing behaviour and vaccine effectiveness.

Two features provide insight into the way the model describes the interaction of the population and Covid-19. The first is the accuracy of the model in modelling the past stages of the epidemic. The second is the ability of the model to predict what will happen if we carry on as we have so far.

Data sources and assumptions

The latest data from Public Health England (PHE) and the Covid-19 Infection Survey of the Office of National Statistics (ONS) [8,9] are used. It is assumed that mitigation efforts in schools will not take place, that lockdown will not be re-imposed and that no new more virulent variant will arrive despite our porous borders and minimal travel restrictions.

The changing transmissibility of the virus—as new variants emerge—is included in the model. Here, we assume that the alpha variant is 50% more transmissible than the original variants and the delta variant is 50% more transmissible than the alpha variant. These assumptions are based on published estimates [10–13].

The model estimates the vaccine effectiveness in relation to transmission, pathogenicity, mortality and protection from infection. To do so it requires prior estimates which are derived from the ONS study and mortality from the PHE study (Table 1).

Table 1 – Prior estimates of vaccine effectiveness in UK up to August 2021

Type of vaccine effectiveness	Source	Description	Prior estimate of vaccine effectiveness
Transmission	ONS	preventing a susceptible person becoming infected after exposure	0.72

Infectiousness	ONS	preventing an infected person infecting others	0.75
Pathogenicity	ONS	preventing an infected person developing Covid-19 disease	0.76
Death	PHE	preventing an infected person dying of Covid-19	0.91

The mix of vaccines used in the UK up to 15th September was ChAdOx1 - 53%, BNT162b2 – 45% and mRNA1273 (Moderna) – 3% [15]. The NHS vaccine scheme by 15th September had provided two doses to 66% of the population [17].

Three scenarios are offered. The first (NPI1) provides the projections with baseline parameters. The second scenario (NPI2) improves the identify, test, trace, isolate and support (FTTIS) system from 30% to 50% successful. The third scenario (NPI3) increases the FTTIS system to 80%.

The latest ONS infection survey dated 4th July finds 835,000 people self-reporting post covid-19 syndrome (symptoms more than twelve weeks after presumed covid-19 infection) [19]. The infections would have occurred before 11th April by which time the model estimated cumulative incidence of 24.9 million (3.36% of cases). This percentage is used to measure the trend in incidence of post covid-19 syndrome.

Software

The figures in Figure 1 can be reproduced using annotated (MATLAB/Octave) code that is available as part of the free and open source academic software SPM. The routines are called by a demonstration script that can be invoked by DEM_COVID, DEM_COVID_X, DEM_COVID_T, DEM_COVID_I or DEM_COVID_LTLA at the MATLAB prompt. At the time of writing, these routines are available in the development version of the next SPM release. An archive of the relevant source code for each publication is available from figshare.

The remaining results in this paper can be reproduced using modified scripts found [here](#).

The routine data used in the manuscripts are available from the COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, Coronavirus (COVID-19) UK Historical Data by Tom White and GOV.UK Coronavirus (COVID-19) in the UK. The CSV files must be available from the MATLAB path. The specific data on vaccine effectiveness are found in the ONS and PHE publications [14,20].

Results

The UK epidemic curve from February 2020 to September 2021

The chosen parameters adjusted by the model reproduce the epidemic curve and infection sequelae experienced by the UK up to now (Figure 1). The model estimates antibody immunity induced by Covid-19 infection and/or vaccine is lost in 284 days.

Figure 1 – Comparing the actual with expected trends in eight measures of the Covid-19 epidemic UK – February 2020 to October 2021

Model predictions up to September 2022

The projections illustrate the depth and persistence of the future epidemic in the UK in terms of morbidity and mortality, transmission characteristics, testing capacity, hospital utilisation and disruption due to acute and chronic symptoms over the next twelve months if the government continues to withhold public health infection control measures (Figure 2).

Figure 2 – projections of the UK epidemic curve – incidence rate, daily confirmed cases, and incidence of long-Covid to March or September 2022

Vaccine effectiveness

The response in the UK to a prolonged wave of Covid-19 infections into the summer of 2022 is moderated by the high vaccine coverage. The vaccines reduce transmission by half compared to the original variants in circulation and pathogenicity for serious illness by 86% and deaths by 93% (Table 2). The effect for an individual is that two dose vaccination reduces the risk of infection from 100% to 37%, and death from 100% to 0.3% (Table 2).

Table 2 – Vaccine effectiveness against Covid-19 Delta variant estimated by DCM model in UK in August 2021

Vaccine effectiveness with respect to Delta variant - September 2021 - UK	Parameter derived from published literature	Estimated by DCM model
Preventing exposure to infection:	75%	63.2% (CI 61.5 to 64.9)
Preventing transmission following infection:	72%	44.2% (CI 40.9 to 47.4)
Preventing serious illness when symptomatic (age 15-34):	76%	85.5% (CI 85.0 to 85.9)
Preventing serious illness when symptomatic (age 35-70):		85.6% (CI 85.2 to 86.1)
Preventing fatality when seriously ill:	91%	93.3% (CI 92.8 to 93.7)
The reduction in risk from 100% after two doses of vaccine		
Relative risk of infection		36.8%
Relative risk of mild illness		32.8%
Relative risk of severe illness		4.7%
Relative risk of fatality		0.3%
CI = 90% Bayesian credible intervals. DCM = dynamic causal model		

The long-term consequences

The trends in morbidity illustrate the consequences of allowing the epidemic to run in an uncontrolled manner through the community in the UK. The model can calculate its cumulative effect on cases numbers, deaths, tests and hospital admissions (Table 3). Tests double, cases increase by two-thirds, hospital admissions by a quarter and deaths by 5% over the coming 12 months. An effective FTTIS system in conjunction with the vaccine programme would more or less stop further cases, hospital admissions and deaths.

Table 3 – the cumulative effect of uncontrolled spread of Covid-19 in the UK – from 1st February 2020 to 1st October 2021 and to 1st October 2022

Cumulative totals since 1st February 2020	1st October 2021	1st October 2022
Scenario assuming FTTIS is 25% effective		
Estimated incidence	37,124,370	60,697,287
Confirmed cases by PCR	7,643,136	16,002,831
Deaths within 28 days of a positive PCR test	136,207	142,437
Tests (both PCR and LFD)	302,707,235	636,316,101
Hospital admissions	536,258	684,004
Post Covid-19 Syndrome	5,117,813	8,265,702
Scenario assuming FTTIS improves to 80% effective on 1st October 2021		
Estimated incidence	37,124,370	37,711,451
Confirmed cases by PCR	7,643,136	7,871,363
Deaths within 28 days of a positive PCR test	136,207	137,216
Tests (both PCR and LFD)	302,707,235	627,227,250
Hospital admissions	536,258	548,438
Post Covid-19 Syndrome	5,117,813	5,198,339

Post Covid-19 Syndrome definition - self reported symptoms more than 12 weeks after presumed Covid-19 infection		
---	--	--

Discussion

The UK provides a baseline of public health inactivity which can be used to compare public health controls chosen by other countries. The vaccines used in the UK seem to be extremely effective at reducing morbidity and mortality although not so effective at reducing transmission. Loss of immunity in 284 days as estimated by the model is similar to the results (extrapolated to 344 days) of the ONS study [14] (Table S4) suggests booster doses of vaccine may be required. The effect of a booster vaccine programme is not modelled.

Despite these very effective vaccines the UK can expect a huge further wave of Covid-19 infections resulting in over 3 million post Covid-19 Syndrome cases, 150,000 hospital admissions and 300 million additional tests. If other mitigating public health measures were employed to support the vaccine effects this further epidemic would be eliminated. Simply making contact tracing effective would achieve that possibility.

The size of the projected wave of infections provides fertile ground for new variants and the absence of border controls will allow new variants from other countries to invade the UK. A health service already exhausted will be rapidly overwhelmed. The lack of effective public health resources will be unable to respond to current or future variants. This means that the UK government may find it has to re-introduce restrictive lockdowns. The excellent scientific institutions in the UK will be able to monitor such features as genomic sequencing, vaccine efficacy, new vaccine trials. How long the population is prepared to be the guinea-pig remains to be seen.

Lessons for other countries are clear. Do not depend solely on vaccination. Relaxation of mitigating public health measures carries a number of risks – overwhelming the health service again, the creation of vaccine resistant variants and the economic cost of huge numbers of acute and chronic cases.

References

1. Friston KJ, Parr T, Zeidman P, Razi A, Flandin G, Daunizeau J, et al. Dynamic causal modelling of COVID-19. Wellcome Open Res. 2020;5: 89. doi:10.12688/wellcomeopenres.15881.2
2. Karl Friston. Dynamic Causal Modelling of COVID-19; dashboard. [cited 24 May 2021]. Available: <https://www.fil.ion.ucl.ac.uk/spm/covid-19/>
3. Gandolfi D, Pagnoni G, Filippini T, Goffi A, Vinceti M, D'Angelo E, et al. Dynamic causal modeling of the COVID-19 pandemic in northern Italy predicts possible scenarios for the second wave. medRxiv. 2020; 2020.08.20.20178798. doi:10.1101/2020.08.20.20178798
4. Moran RJ, Fagerholm ED, Cullen M, Daunizeau J, Richardson MP, Williams S, et al. Estimating required “lockdown” cycles before immunity to SARS-CoV-2: Model-based analyses of susceptible population sizes, “S0”, in seven European countries including the UK and Ireland. arXiv:200405060 [q-bio]. 2020 [cited 27 Sep 2021]. Available: <http://arxiv.org/abs/2004.05060>
5. Daunizeau J, Moran R, Brochard J, Mattout J, Frackowiak R, Friston K. Modelling lockdown-induced 2nd COVID waves in France. 2020 Jul p. 2020.06.24.20139444. doi:10.1101/2020.06.24.20139444
6. Dynamic Causal Modelling of COVID-19 and Australian Projections. [cited 27 Sep 2021]. Available: <http://www.adeelrazi.org/predictions.html>
7. Friston KJ, Parr T, Zeidman P, Razi A, Flandin G, Daunizeau J, et al. Second waves, social distancing, and the spread of COVID-19 across the USA. Wellcome Open Res. 2021;5: 103. doi:10.12688/wellcomeopenres.15986.3
8. PHE. SARS-CoV-2 variants of concern and variants under investigation. 2021; 44.

9. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. 2021; 39.
10. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. 2021;372. doi:10.1126/science.abg3055
11. Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. The effect of SARS-CoV-2 variant B.1.1.7 on symptomatology, re-infection and transmissibility. *medRxiv*. 2021; 2021.01.28.21250680. doi:10.1101/2021.01.28.21250680
12. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. *Eurosurveillance*. 2021;26: 2100509. doi:10.2807/1560-7917.ES.2021.26.24.2100509
13. Dagpunar J. Interim estimates of increased transmissibility, growth rate, and reproduction number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom. 2021 Jun p. 2021.06.03.21258293. doi:10.1101/2021.06.03.21258293
14. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine*. 2021;385: 585–594. doi:10.1056/NEJMoa2108891
15. Coronavirus vaccine - weekly summary of Yellow Card reporting. In: GOV.UK [Internet]. [cited 27 Sep 2021]. Available: <https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting>
16. MHRA. Coronavirus vaccine - weekly summary of Yellow Card reporting. In: GOV.UK [Internet]. [cited 16 Aug 2021]. Available: <https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting>
17. Public Health England. COVID-19 vaccine surveillance report - week 38. 2021; 33.
18. Public Health England. COVID-19 vaccine surveillance report - week 33. 2021; 24.
19. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK - Office for National Statistics. [cited 29 Aug 2021]. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/alldatarelatingtoprevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk>
20. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *medRxiv*. 2021; 2021.08.18.21262237. doi:10.1101/2021.08.18.21262237

medRxiv preprint doi: <https://doi.org/10.1101/2021.10.04.21262827>; this version posted October 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

ONS relates to Office of National Statistics and GOV to NHS and Department of Health published data and shown in black dots. Blue lines and shade are DCM estimates with 90% Bayesian credible intervals. Ages 16-35 years = blue; 35-70 years = red; 70+ years = yellow

Prevalence and reproduction ratio (04-Oct-21): R = 0.87 (CI 0.69 to 1.05)

Number of people with Covid-19 symptoms

Daily incidence of new infections (%)

Incidence of long COVID (assuming affects 3.36% of incidence cases)

Number of daily deaths (28 days)

Number of people in hospital with Covid-19

CI is 90% Bayesian credible intervals; R DCM is the reproductive number calculated by the DCM; R SPI-M is the published estimates of the government SPI-M-O committee; R0 is an estimate of the changing underlying transmissibility of the viruses in circulation. This estimate includes seasonality effects and may rise to about 6 as winter approaches. Scenarios: NPI1 – base-line predictions; NPI2 – Find, test, trace, isolate, Support (FTTIS) improved from 27% to 50% effective on 1st October 2021; NPI3 – FTTIS improved from 30% to 80% effective (80% close contacts isolate within 3 days) on 1st October 2021. Long-covid assumed to occur in 3.36% of incident cases.